Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23


N-acetylcysteine inhibits thrombosis in a murine model of myeloproliferative neoplasm.

Craver BM, Ramanathan G, Hoang S, Chang X, Mendez Luque LF, Brooks S, Lai HY, Fleischman AG.

Blood Adv. 2020 Jan 28;4(2):312-321. doi: 10.1182/bloodadvances.2019000967.


The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells.

Craver BM, Nguyen TK, Nguyen J, Nguyen H, Huynh C, Morse SJ, Fleischman AG.

Exp Hematol Oncol. 2020 Jan 2;9:1. doi: 10.1186/s40164-019-0157-6. eCollection 2020.


Upregulation of endogenous thrombopoietin receptor (MPL) with in vivo passage of calreticulin (CALR) mutant Ba/F3 cells, highlighting MPL as the requisite cytokine receptor for CALR mediated transformation.

Brooks SA, Kim DM, Morse SJ, Nguyen QH, Craver BM, Lai HY, Fleischman AG.

Leuk Res. 2019 Jul;82:11-14. doi: 10.1016/j.leukres.2019.05.003. Epub 2019 May 9. No abstract available.


Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms.

Mendez Luque LF, Blackmon AL, Ramanathan G, Fleischman AG.

Curr Hematol Malig Rep. 2019 Jun;14(3):145-153. doi: 10.1007/s11899-019-00508-w. Review.


Defective negative regulation of Toll-like receptor signaling leads to excessive TNF-α in myeloproliferative neoplasm.

Lai HY, Brooks SA, Craver BM, Morse SJ, Nguyen TK, Haghighi N, Garbati MR, Fleischman AG.

Blood Adv. 2019 Jan 22;3(2):122-131. doi: 10.1182/bloodadvances.2018026450.


Statins enhance efficacy of venetoclax in blood cancers.

Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, Mallya S, Bellin RJ, Agarwal SK, Salem AH, Xu T, Jia J, Li L, Hanna JR, Davids MS, Fleischman AG, O'Brien S, Lam LT, Leverson JD, Letai A, Schatz JH, Fruman DA.

Sci Transl Med. 2018 Jun 13;10(445). pii: eaaq1240. doi: 10.1126/scitranslmed.aaq1240.


The Critical Role of Inflammation in the Pathogenesis and Progression of Myeloid Malignancies.

Craver BM, El Alaoui K, Scherber RM, Fleischman AG.

Cancers (Basel). 2018 Apr 3;10(4). pii: E104. doi: 10.3390/cancers10040104. Review.


Determining the role of inflammation in the selection of JAK2 mutant cells in myeloproliferative neoplasms.

Zhang J, Fleischman AG, Wodarz D, Komarova NL.

J Theor Biol. 2017 Jul 21;425:43-52. doi: 10.1016/j.jtbi.2017.05.012. Epub 2017 May 10.


Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm.

Nguyen TK, Morse SJ, Fleischman AG.

J Vis Exp. 2016 Dec 22;(118). doi: 10.3791/54624.


Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm.

Fleischman AG.

Mediators Inflamm. 2015;2015:606819. doi: 10.1155/2015/606819. Epub 2015 Oct 11. Review.


JAK2(V617I) results in cytokine hypersensitivity without causing an overt myeloproliferative disorder in a mouse transduction-transplantation model.

Brooks SA, Luty SB, Lai HY, Morse SJ, Nguyen TK, Royer LR, Agarwal A, Druker BJ, Fleischman AG.

Exp Hematol. 2016 Jan;44(1):24-9.e1. doi: 10.1016/j.exphem.2015.09.006. Epub 2015 Oct 13.


BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein.

Agarwal A, Mackenzie RJ, Besson A, Jeng S, Carey A, LaTocha DH, Fleischman AG, Duquesnes N, Eide CA, Vasudevan KB, Loriaux MM, Firpo E, Cortes JE, McWeeney S, O'Hare T, Roberts JM, Druker BJ, Deininger MW.

Blood. 2014 Nov 20;124(22):3260-73. doi: 10.1182/blood-2013-04-497040. Epub 2014 Oct 7.


Causal role for JAK2 V617F in thrombosis.

Fleischman AG, Tyner JW.

Blood. 2013 Nov 28;122(23):3705-6. doi: 10.1182/blood-2013-10-531665. No abstract available.


The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.

Fleischman AG, Maxson JE, Luty SB, Agarwal A, Royer LR, Abel ML, MacManiman JD, Loriaux MM, Druker BJ, Tyner JW.

Blood. 2013 Nov 21;122(22):3628-31. doi: 10.1182/blood-2013-06-509976. Epub 2013 Sep 30.


Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.

Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW.

N Engl J Med. 2013 May 9;368(19):1781-90. doi: 10.1056/NEJMoa1214514.


TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.

Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH, Yost A, Ma W, Fleischman AG, Zhou W, Yang Y, Kleppe M, Ahn Y, Tatarek J, Kelliher MA, Neuberg DS, Levine RL, Moriggl R, Müller M, Gray NS, Jamieson CH, Weng AP, Staudt LM, Druker BJ, Look AT.

Cancer Discov. 2013 May;3(5):564-77. doi: 10.1158/2159-8290.CD-12-0504. Epub 2013 Mar 7.


Hematopoietic stem cell transplantation for myelofibrosis: where are we now?

Fleischman AG, Maziarz RT.

Curr Opin Hematol. 2013 Mar;20(2):130-6. doi: 10.1097/MOH.0b013e32835dd862. Review.


Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.

Agarwal A, Fleischman AG, Petersen CL, MacKenzie R, Luty S, Loriaux M, Druker BJ, Woltjer RL, Deininger MW.

Blood. 2012 Sep 27;120(13):2658-68. Epub 2012 Aug 13.


JAK2 V617F down-modulates MPL.

Fleischman AG, Tyner JW.

Blood. 2012 May 17;119(20):4579-80. doi: 10.1182/blood-2012-03-417261.


ALDH marks leukemia stem cell.

Fleischman AG.

Blood. 2012 Apr 12;119(15):3376-7. doi: 10.1182/blood-2012-02-406751.


TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.

Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, Vasudevan KB, LaTocha DH, Yang F, Press RD, Loriaux MM, Pahl HL, Silver RT, Agarwal A, O'Hare T, Druker BJ, Bagby GC, Deininger MW.

Blood. 2011 Dec 8;118(24):6392-8. doi: 10.1182/blood-2011-04-348144. Epub 2011 Aug 22.


The stem cell fitness landscape and pathways of molecular leukemogenesis.

Bagby GC, Fleischman AG.

Front Biosci (Schol Ed). 2011 Jan 1;3:487-500. Review.


Same mutation, different allele.

Aichberger KJ, Fleischman AG, Deininger MW.

Blood. 2009 Oct 1;114(14):2853-4. doi: 10.1182/blood-2009-07-229906. No abstract available.


Supplemental Content

Loading ...
Support Center